Abstract
The main goal of early phase trials is to gain knowledge about the clinical suitability of novel compounds, without pursuing specific therapeutic purposes. Healthy volunteers usually represent the ideal model for conducting phase I clinical trials, in order to investigate pharmacokinetics and pharmacodynamics as well as to document safety and tolerability without interference by concomitant pathological conditions. The increasing cost of novel drug development, in conjunction with ethical considerations, has fostered a new procedure for first-in-man trials, designated as “phase 0,” which is conducted very early on a limited number of healthy volunteers who are exposed to low drug levels. The present review discusses issues concerning the enrollment of healthy volunteers in the early phase of drug development from different points of view, with some focus on the Italian experience. From the ethical standpoint, much discussion revolves around payments to healthy volunteers. Most authors agree that an adequate remuneration must be provided to healthy subjects, while avoiding coercion and excessive psychological pressure. Pending the lack of international and national guidelines, our center for clinical drug experimentation has implemented an operative procedure to estimate payments for healthy volunteers based on specific items, including restriction, time spent, discomfort, and risk. Other unresolved issues about the recruitment of healthy volunteers are represented by the lack of international consensus on the definition of healthy status and the need for guidelines about advertisement on clinical trials addressed to potential participants.
Similar content being viewed by others
References
Pocock SJ (1983) Clinical trials: a practical approach. Wiley, Chichester
Buoen C, Bjerrum OJ, Thomsen MS (2005) How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 45:1123–1136
Friedman LF, Furberg C, DeMets DL (1998) Fundamentals of clinical trials. Springer-Verlag, New York
EMEA (2004) Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP/2599/02/Rev 1. http://www.ema.europa.eu/pdfs/human/swp/259902en.pdf. Accessed 23 March 2010
Del Tacca M, Pasqualetti G, Di Paolo A, Virdis A, Massimetti G, Gori G, Versari D, Taddei S, Blandizzi C (2009) Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol 68:34–42
Royal College of Physicians (1986) Research on healthy volunteers. J R Coll Physicians 20:243–257
Association of British Pharmaceuticals Industries (1988) Guidelines for medical experimentation in non-patient human volunteers. ABPI, London
EMEA (1998) Pharmacokinetic studies in man. 3CC3A. http://www.ema.europa.eu/pdfs/human/ewp/3cc3aen.pdf. Accessed 11 January 2010
World Medical Association (2008) Declaration of Helsinki—ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 11 January 2010
EMEA (2002) Guideline for good clinical practice. ICH Topic E 6 (R1). http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf. Accessed 11 January 2010
EMEA (2009) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. ICH topic M3, CPMP/ICH/286/95. http://www.ema.europa.eu/pdfs/human/ich/028695en.pdf. Accessed 11 January 2010
EMEA (2007) Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. CHMP/SWP/28367/07. http://www.ema.europa.eu/pdfs/human/swp/2836707enfin.pdf. Accessed 11 January 2010
EMEA (2007) Recommendation on the need for revision of CHMP. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/9816. http://www.ema.europa.eu/pdfs/human/ewp/20094307en.pdf. Accessed 11 January 2010
Schellens JH (2009) Phase 0 (zero) clinical trials: more than zero benefit? Eur J Cancer 45:728–729
Hill TP (2007) Phase 0 trials: are they ethically challenged? Clin Cancer Res 13:783–784
EMEA (2006) Concept paper on development of a CHMP guideline on the non-clinical requirements to support early phase I clinical trials with pharmaceutical compounds. EMEA/CHMP/SWP/91850/2006. http://www.ema.europa.eu/pdfs/human/swp/9185006en.pdf. Accessed 23 March 2010
FDA (2006) Guidance for industry, investigators, and reviewers. Exploratory IND studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf. Accessed 23 March 2010
Harris PA, Lane L, Biaggioni I (2005) Clinical research subject recruitment: the Volunteer for Vanderbilt Research Program www.volunteer.mc.vanderbilt.edu. J Am Med Inform Assoc 12:608–613
Bramstedt KA (2007) Recruiting healthy volunteers for research participation via internet advertising. Clin Med Res 5:91–97
Dickert N, Emanuel E, Grady C (2002) Paying research subjects: an analysis of current policies. Ann Intern Med 136:368–373
Iltis AS (2009) Payments to normal healthy volunteers in phase I trials: avoiding undue influence while distributing fairly the burdens of research participation. Med Philos 34:68–90
Wilkinson M (2005) Payments to research subjects. Monash Bioeth Rev 24:70–74
Grady C, Dickert N, Jawetz T, Gensler G, Emanuel E (2005) An analysis of U.S. practices of paying research participants. Contemp Clin Trials 26:365–375
Bentley JP, Thacker PG (2004) The influence of risk and monetary payment on the research participation decision making process. Med Ethics 30:293–298
Schonfeld TL, Brown JS, Weniger M, Gordon B (2003) Research involving the homeless: arguments against payment in kind. IRB 25:17–20
Sears JM (2001) Payment of research subjects: a broader perspective. Am J Bioeth 1:66–67
Wilkinson M, Moore A (1999) Inducements revisited. Bioethics 13:114–130
McNeill P (1997) Paying people to participate in research: why not? A response to Wilkinson and Moore. Bioethics 11:390–396
Resnick DB (2008) Increasing the amount of payment to research subjects. Med Ethics 34:14
Bechtel PR, Alvan G (1989) Criteria for the choice and definition of healthy volunteers and or patients for phase I and phase II studies in drug development. Commentary on an action for cooperative research. Eur J Clin Pharmacol 36:549–550
Kenter MJ, Cohen AF (2006) Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368:1387–1391
EMEA (2007) Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products. CHMP/SWP/28367/2007. http://www.ema.europa.eu/pdfs/human/swp/2836707en.pdf. Accessed 11 January 2010
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pasqualetti, G., Gori, G., Blandizzi, C. et al. Healthy volunteers and early phases of clinical experimentation. Eur J Clin Pharmacol 66, 647–653 (2010). https://doi.org/10.1007/s00228-010-0827-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0827-0